Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$27.58 USD

27.58
3,889,579

-0.60 (-2.13%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $27.00 -0.58 (-2.10%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.

Compared to Estimates, Perrigo (PRGO) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Perrigo (PRGO) Q2 Earnings Top Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of 10.42% and 5.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Green Thumb Industries Inc. (GTBIF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Green Thumb Industries Inc. (GTBIF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Understanding Perrigo (PRGO) Reliance on International Revenue

Explore how Perrigo's (PRGO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates

Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.

Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kinjel Shah headshot

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

Insights Into Perrigo (PRGO) Q1: Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View

Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.

Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ahead of Perrigo (PRGO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Perrigo (PRGO) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 16.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Up 2.9% Since Last Earnings Report: Can It Continue?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Up 2% Since Last Earnings Report: Can It Continue?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.

Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Perrigo (PRGO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates

Cerus (CERS) delivered earnings and revenue surprises of 40% and 2.76%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?